An observational study in Liver Fibrosis, Liver Cirrhosis and NAFLD (Nonalcoholic Fatty Liver Disease), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Second Affiliated Hospital of Xi'an Jiaotong University · Observational
Liver stiffness measurement is a key non-invasive tool for assessing liver fibrosis and cirrhosis in patients with chronic liver disease. Transient elastography (FibroScan) is currently the most widely used non-invasive reference standard, but it requires a dedicated device and trained operator, which may limit its accessibility in some clinical settings. This study aims to evaluate the diagnostic accuracy of a novel wearable patch-type ultrasound probe for detecting significant liver fibrosis and cirrhosis, using FibroScan as the reference standard. Patients with chronic liver disease will undergo simultaneous liver stiffness measurement using both the wearable patch ultrasound probe and FibroScan. The diagnostic performance of the patch probe, including sensitivity, specificity, and area under the receiver operating characteristic curve (AUC), will be evaluated against fibrosis staging determined by FibroScan, along with the correlation and agreement between the two measurement methods.
Chronic liver disease, including chronic viral hepatitis, non-alcoholic fatty liver disease (NAFLD), and alcohol-related liver disease, can progress to liver fibrosis and, ultimately, cirrhosis if left undetected and untreated. Accurate and timely assessment of liver fibrosis stage is essential for guiding clinical management, including treatment initiation, monitoring of disease progression, and screening for cirrhosis-related complications such as esophageal varices and hepatocellular carcinoma.
Liver biopsy has traditionally been considered the gold standard for assessing liver fibrosis; however, it is invasive, carries risk of complications, and is subject to sampling variability. Transient elastography (FibroScan) has emerged as a widely validated non-invasive alternative, providing a reliable estimate of liver stiffness that correlates with fibrosis stage. However, FibroScan requires a dedicated, non-portable device and a trained operator, and access may be limited in certain clinical settings, particularly outside of specialized hepatology centers.
Wearable ultrasound technology has advanced substantially in recent years, offering the potential for a simplified, patch-type probe that can be applied directly to the skin over the liver to estimate tissue stiffness. Such a device could potentially lower the technical barrier for liver stiffness assessment and expand access to non-invasive fibrosis screening. However, the diagnostic accuracy of this wearable patch-type ultrasound probe for detecting clinically significant fibrosis and cirrhosis has not yet been established in a clinical population.
This study is a prospective cross-sectional diagnostic accuracy study. Patients with chronic liver disease will be enrolled and will undergo liver stiffness measurement using both the investigational wearable patch-type ultrasound probe and FibroScan (transient elastography) at the same clinical visit. FibroScan results will be used as the reference standard to classify patients according to fibrosis stage, including significant fibrosis (≥F2) and cirrhosis (F4). The diagnostic performance of the wearable patch ultrasound probe will be evaluated by calculating sensitivity, specificity, positive predictive value, negative predictive value, and the area under the receiver operating characteristic curve (AUC) for each clinically relevant fibrosis threshold, along with the corresponding optimal cut-off values. In addition, the correlation and agreement between liver stiffness values obtained from the wearable patch probe and FibroScan will be assessed using Pearson correlation coefficient and Bland-Altman analysis.
The results of this study are expected to provide preliminary evidence on whether the wearable patch-type ultrasound probe can serve as a reliable, accessible, non-invasive tool for the diagnosis of liver fibrosis and cirrhosis in patients with chronic liver disease.
1,298 studies on the registry are indexed under Liver Cirrhosis; 338 are open to participants now.
This study's planned enrollment of 150 is below the median of 171 across 526 observational studies indexed under Liver Cirrhosis.
Browse Liver Cirrhosis studies →Second Affiliated Hospital of Xi'an Jiaotong University is the lead sponsor of 70 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with confirmed or suspected chronic liver disease (including chronic viral hepatitis, non-alcoholic fatty liver disease, and alcohol-related liver disease) presenting for routine clinical evaluation, consecutively enrolled to capture a continuous spectrum of liver fibrosis severity ranging from no/mild fibrosis to cirrhosis. All eligible patients will undergo liver stiffness measurement using both the investigational wearable patch-type ultrasound probe and transient elastography (FibroScan) as the reference standard.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Wearable Patch-Type Ultrasound Probe · Device: Transient Elastography (FibroScan)
An investigational patch-type ultrasound probe applied to the skin over the liver to non-invasively estimate liver tissue stiffness. Measurement results will be compared against the reference standard to evaluate diagnostic accuracy for detecting significant fibrosis and cirrhosis.
A validated, widely used non-invasive reference standard device for measuring liver stiffness, used to classify patients according to fibrosis stage (e.g., significant fibrosis ≥F2, cirrhosis F4).
Area Under the Receiver Operating Characteristic Curve (AUC) for Detecting Significant Liver Fibrosis (≥F2)
The AUC of the wearable patch ultrasound probe for distinguishing patients with significant fibrosis (≥F2) from those with no/mild fibrosis (F0-F1), using FibroScan-determined fibrosis stage as the reference standard.
Time frame: Baseline (Day 1)
Area Under the Receiver Operating Characteristic Curve (AUC) for Detecting Cirrhosis (F4)
The AUC of the wearable patch ultrasound probe for distinguishing patients with cirrhosis (F4) from those without cirrhosis (F0-F3), using FibroScan-determined fibrosis stage as the reference standard.
Time frame: Baseline (Day 1)
Correlation and Agreement Between Wearable Patch Ultrasound Probe and Reference Standard Liver Stiffness Measurements
Agreement between liver stiffness values obtained from the wearable patch ultrasound probe and the reference standard (FibroScan) will be assessed using Pearson correlation coefficient and Bland-Altman analysis to evaluate systematic bias and limits of agreement across the full range of measured values.
Time frame: At the time of enrollment (single time-point assessment)
Correlation Coefficient Between Wearable Patch Ultrasound Probe and FibroScan Liver Stiffness Measurements, Stratified by Fibrosis Severity Subgroup
Patients will be stratified into subgroups based on FibroScan-determined fibrosis stage (no/mild fibrosis \[F0-F1\], significant fibrosis \[F2-F3\], and cirrhosis \[F4\]). Within each subgroup, the Pearson correlation coefficient between liver stiffness values (measured in kPa) obtained from the wearable patch ultrasound probe and FibroScan will be calculated to assess whether measurement agreement varies with disease severity.
Time frame: Baseline (Day 1)
Sensitivity of the Wearable Patch Ultrasound Probe for Detecting Significant Liver Fibrosis (≥F2)
Sensitivity of the wearable patch ultrasound probe, at the optimal cut-off value, for detecting significant fibrosis (≥F2), using FibroScan-determined fibrosis stage as the reference standard.
Time frame: Baseline (Day 1)
Specificity of the Wearable Patch Ultrasound Probe for Detecting Significant Liver Fibrosis (≥F2)
Specificity of the wearable patch ultrasound probe, at the optimal cut-off value, for detecting significant fibrosis (≥F2), using FibroScan-determined fibrosis stage as the reference standard.
Time frame: Baseline (Day 1)
Sensitivity of the Wearable Patch Ultrasound Probe for Detecting Cirrhosis (F4)
Sensitivity of the wearable patch ultrasound probe, at the optimal cut-off value, for detecting cirrhosis (F4), using FibroScan-determined fibrosis stage as the reference standard.
Time frame: Baseline (Day 1)
Specificity of the Wearable Patch Ultrasound Probe for Detecting Cirrhosis (F4)
Specificity of the wearable patch ultrasound probe, at the optimal cut-off value, for detecting cirrhosis (F4), using FibroScan-determined fibrosis stage as the reference standard.
Time frame: Baseline (Day 1)
Positive Predictive Value (PPV) of the Wearable Patch Ultrasound Probe for Detecting Significant Liver Fibrosis (≥F2)
PPV of the wearable patch ultrasound probe, at the optimal cut-off value, for detecting significant fibrosis (≥F2), using FibroScan-determined fibrosis stage as the reference standard.
Time frame: Baseline (Day 1)
Negative Predictive Value (NPV) of the Wearable Patch Ultrasound Probe for Detecting Significant Liver Fibrosis (≥F2)
NPV of the wearable patch ultrasound probe, at the optimal cut-off value, for detecting significant fibrosis (≥F2), using FibroScan-determined fibrosis stage as the reference standard.
Time frame: Baseline (Day 1)
Correlation and Agreement Between Wearable Patch Ultrasound Probe and FibroScan Liver Stiffness Measurements
Agreement between liver stiffness values obtained from the wearable patch ultrasound probe and FibroScan will be assessed using Pearson correlation coefficient and Bland-Altman analysis to evaluate systematic bias and limits of agreement.
Time frame: Baseline (Day 1)
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital of Xi'an Jiaotong University